Phase I-IV clinical trials excellence
MAC Clinical Research is one Europe's largest clinical development organisations. Owning a network of Dedicated Research Sites providing extensive reach, MAC has offices within the EU and US. Our clinical research organisation is committed totally to the recruitment and conduct of clinical trials and full-service delivery through our fully owned Dedicated Research Sites and staff. Although our heritage stems from being the first memory assessment centre based in Europe, our company conducts research for sponsors over an ever expanding group of therapeutic areas. MAC has an extensive range of clinical research capabilities to accommodate the most complex Phase 1 trials (in our MHRA Accredited Phase 1 Unit Read More) through to Phase IV (across our network of late phase Dedicated Research Sites). The majority of our current work includes CNS diseases (e.g. Alzheimer's and Multiple Sclerosis), analgesics (acute and chronic pain), dermatology (psoriasis and eczema), rheumatology (fibromyalgia and arthritis), endocrinological diseases (e.g. diabetes) depression, anxiety and insomnia.
With Eight Dedicated Research Sites across the country (including seven late phase and one MHRA Accredited Phase 1 Unit) MAC has ease of access to over 20 million patients in the UK alone.
MAC’s Recruitment Centre provides excelled recruitment of patients for all studies, often reaching target figures ahead of study timelines. With over 200 clinical studies successfully completed, and extensive therapeutic expertise, MAC’s full-service offering to pharma, biotech and CROs continues to strengthen with significant growth.
MAC's privately owned Dedicated Research Sites provide an efficient and effective option for conducting clinical trials, which avoids unnecessary delays. In fact, MAC's lead-time through the regulatory submissions process currently takes 35 days in total.